AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31190757 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group), visits at the general practice.
Number of subjects: 108
Study 30217693 — intervention group
Group type: EXPERIMENTAL
Intervention: LBP+Hip group
Number of subjects: 76
Study 30217693 — intervention group
Group type: COMPARATOR
Intervention: LBP only group
Number of subjects: 76
Study 27295444 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCIS low rate (750 pps/ch)
Number of subjects: 26
Study 27295444 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCIS high rate (1376 pps/ch)
Number of subjects: 26
Study 27295444 — intervention group
Group type: EXPERIMENTAL
Intervention: FS4 low rate (750 pps/ch)
Number of subjects: 26
Study 27295444 — intervention group
Group type: EXPERIMENTAL
Intervention: FS4 high rate (1376 pps/ch)
Number of subjects: 26
Study 27295444 — intervention group
Group type: EXPERIMENTAL
Intervention: FS4 high rate
Number of subjects: 26
Study 27295444 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCIS high rate
Number of subjects: 26
Study 27295444 — intervention group
Group type: EXPERIMENTAL
Intervention: FS4 low rate
Number of subjects: 26
Study 24138089 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness training
Number of subjects: 103
Study 24138089 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 103
Study 22526531 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (4 weeks pre-quit)
Number of subjects: 57
Study 22526531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 weeks)
Number of subjects: 57
Study 20522594 — intervention group
Group type: EXPERIMENTAL
Intervention: TUDCA (1,750 mg/day)
Number of subjects: 20
Study 20522594 — intervention group
Group type: EXPERIMENTAL
Intervention: TUDCA
Number of subjects: 20
Study 20522594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18622965 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative duplex ultrasonography (IODS)
Number of subjects: 70
Study 18622965 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal or corrected relevant findings)
Number of subjects: 70
Study 15642073 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR 1000 mg once daily
Number of subjects: 982
Study 15642073 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR 500 mg once daily
Number of subjects: 982
Study 15642073 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR 1500 mg once daily
Number of subjects: 982
Study 15642073 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR 2000 mg once daily
Number of subjects: 982
Study 15642073 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR 1000 mg twice daily
Number of subjects: 982
Study 15642073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 982
Study 15642073 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR
Number of subjects: 982
Study 12103287 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (50 Gy in 25 fractions)
Number of subjects: 190
Study 12103287 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy (66 Gy in 33 fractions)
Number of subjects: 190
Study 12103287 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 190
Study 12103287 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 190
Study 10082501 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant coffee (5 cups per day, equivalent to 300 mg caffeine per day)
Number of subjects: 48
Study 10082501 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free diet (abstaining from caffeine-containing drinks)
Number of subjects: 48
Study 7579751 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 6
Study 7579751 — intervention group
Group type: COMPARATOR
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 6
Study 2202240 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Mylanta II)
Number of subjects: 73
Study 2202240 — intervention group
Group type: EXPERIMENTAL
Intervention: GI cocktail (antacid + 15 mL of 2% viscous lidocaine)
Number of subjects: 73
Study 7156248 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan
Number of subjects: 115
Study 7156248 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 115
Study 7156248 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan-amitriptyline combination
Number of subjects: 115
Study 7156248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 30921384 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 53
Study 30921384 — intervention group
Group type: COMPARATOR
Intervention: Episodic Recent Thinking (ERT)
Number of subjects: 53
Study 30921384 — intervention group
Group type: COMPARATOR
Intervention: Standardized Episodic Thinking (SET)
Number of subjects: 53
Study 29514254 — intervention group
Group type: EXPERIMENTAL
Intervention: Late pregnancy
Number of subjects: 2751
Study 29514254 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum period
Number of subjects: 2751
Study 29514254 — intervention group
Group type: COMPARATOR
Intervention: Nonpregnant period
Number of subjects: 2751
Study 29514254 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pregnancy
Number of subjects: 2751
Study 27647120 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial rectus muscle pulley fixation (pulley group)
Number of subjects: 60
Study 27647120 — intervention group
Group type: COMPARATOR
Intervention: Augmented medial rectus muscle recession (augmented group)
Number of subjects: 60
Study 27129009 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2151 (100, 200, or 400 mg daily for 3 days)
Number of subjects: 0
Study 27129009 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2151 (1,200 mg as a single dose)
Number of subjects: 0
Study 27129009 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 0
Study 27129009 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (500 mg twice daily for 3 days)
Number of subjects: 0
Study 22389220 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly efficient face mask
Number of subjects: 98
Study 22389220 — intervention group
Group type: COMPARATOR
Intervention: No mask (control)
Number of subjects: 98
Study 18214702 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based teaching (SBT)
Number of subjects: 33
Study 18214702 — intervention group
Group type: COMPARATOR
Intervention: Problem-based discussion (PBD)
Number of subjects: 33
Study 17179772 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal single-dose cream (CVSDC)
Number of subjects: 55
Study 17179772 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole vaginal gel (MVG)
Number of subjects: 55
Study 15159307 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for the T allele at position -509
Number of subjects: 492
Study 15159307 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for the C allele at position +29
Number of subjects: 492
Study 15159307 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 492
Study 12428241 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose D-Penicillamine
Number of subjects: 134
Study 12428241 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose D-Penicillamine
Number of subjects: 134
Study 12428241 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone use at entry
Number of subjects: 134
Study 12428241 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin scores
Number of subjects: 134
Study 12428241 — intervention group
Group type: EXPERIMENTAL
Intervention: SRC
Number of subjects: 134
Study 12428241 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival after SRC
Number of subjects: 134
Study 9839295 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg
Number of subjects: 48
Study 9839295 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 5 mg
Number of subjects: 48
Study 8209936 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 492
Study 8209936 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 492
Study 2492170 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine solution (0.8 mg/kg)
Number of subjects: 13
Study 2492170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31085282 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb treatment based on voluntary task‐oriented movements
Number of subjects: 30
Study 31085282 — intervention group
Group type: COMPARATOR
Intervention: Passive mobilization of shoulder, elbow, wrist and fingers (Control)
Number of subjects: 30
Study 28295516 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% BPO gel
Number of subjects: 609
Study 28295516 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% BPO gel
Number of subjects: 609
Study 28295516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 26268495 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy combined with metoprolol
Number of subjects: 56
Study 26268495 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 56
Study 23696477 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Programme (ERP)
Number of subjects: 91
Study 23696477 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 91
Study 21718338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.28 water/powder ratio of white MTA
Number of subjects: 29
Study 21718338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33 water/powder ratio of white MTA
Number of subjects: 29
Study 21718338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.40 water/powder ratio of white MTA
Number of subjects: 29
Study 19327624 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 82
Study 19327624 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 82
Study 19327624 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 82
Study 16678480 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV uninfected children
Number of subjects: 39836
Study 16678480 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infected children
Number of subjects: 39836
Study 16678480 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born at <36 weeks of gestational age (GA)
Number of subjects: 39836
Study 16678480 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born at <36 weeks of GA
Number of subjects: 39836
Study 16678480 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born at <32 weeks of GA
Number of subjects: 39836
Study 15049397 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper diary
Number of subjects: 87
Study 15049397 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRS diary
Number of subjects: 87
Study 15049397 — intervention group
Group type: COMPARATOR
Intervention: Both instruments
Number of subjects: 87
Study 11370940 — intervention group
Group type: EXPERIMENTAL
Intervention: Beryllium Exposure Control Program including air monitoring, surface contamination controls, building design, engineering controls, worker controls, material controls, and medical surveillance.
Number of subjects: 194
Study 11370940 — intervention group
Group type: EXPERIMENTAL
Intervention: Area sampling concentrations
Number of subjects: 194
Study 9260070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 8
Study 9260070 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 8
Study 9260070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9260070 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 8
Study 9260070 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 8
Study 9260070 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 8
Study 8320728 — intervention group
Group type: COMPARATOR
Intervention: 4-aminopyridine (4-AP) administered via infusion over 2 hours, with a total escalating dose from 18.0 to 33.5 mg.
Number of subjects: 8
Study 8320728 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo administered via infusion over 2 hours.
Number of subjects: 8
Study 3505267 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine chest physiotherapy and suction
Number of subjects: 20
Study 3505267 — intervention group
Group type: COMPARATOR
Intervention: Suction only
Number of subjects: 20
Study 31173921 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy informed by Acceptance and Commitment Therapy (PACT)
Number of subjects: 248
Study 31173921 — intervention group
Group type: COMPARATOR
Intervention: Usual care physical therapy
Number of subjects: 248
Study 30326045 — intervention group
Group type: EXPERIMENTAL
Intervention: hu3F8 (humanized anti-GD2 antibody) infused intravenously for 30 minutes on Monday, Wednesday, and Friday, with dosage escalation up to 9.6 mg/kg/cycle (approximately 288 mg/m2)
Number of subjects: 57
Study 30326045 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor administered subcutaneously daily from 5 days before infusion through the last day of infusion
Number of subjects: 57
Study 30326045 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosing of hu3F8
Number of subjects: 57
Study 27768571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree oil
Number of subjects: 20
Study 27768571 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexanide
Number of subjects: 20
Study 27768571 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine
Number of subjects: 20
Study 27768571 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20
Study 24582868 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lenses of +0.50 D, +2.00 D, +5.00 D, +8.00 D
Number of subjects: 6
Study 24582868 — intervention group
Group type: COMPARATOR
Intervention: Control (no contact lens)
Number of subjects: 6
Study 22952551 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 or 6mg) combined with methylphenidate (1mg/kg)
Number of subjects: 0
Study 22952551 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with methylphenidate (1mg/kg)
Number of subjects: 0
Study 20557557 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectacles
Number of subjects: 0
Study 20557557 — intervention group
Group type: COMPARATOR
Intervention: Contact lenses
Number of subjects: 0
Study 18936215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine intake of 10 mg x kg(‐1) x d(‐1)
Number of subjects: 4
Study 18936215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine intake of 20 mg x kg(‐1) x d(‐1)
Number of subjects: 4
Study 18936215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine intake of 30 mg x kg(‐1) x d(‐1)
Number of subjects: 4
Study 18936215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine intake of 40 mg x kg(‐1) x d(‐1)
Number of subjects: 4
Study 18936215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine intake of 0 mg x kg(‐1) x d(‐1)
Number of subjects: 4
Study 18936215 — intervention group
Group type: COMPARATOR
Intervention: Cysteine intake (all levels)
Number of subjects: 4
Study 15800508 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐management Program of the Stanford University
Number of subjects: 120
Study 15800508 — intervention group
Group type: COMPARATOR
Intervention: 6‐month wait‐list control group
Number of subjects: 120
Study 12578880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with enalapril or nisoldipine; mean blood pressure of 128/75 mm Hg over 4 years.
Number of subjects: 950
Study 12578880 — intervention group
Group type: COMPARATOR
Intervention: Moderate blood pressure control (placebo); mean blood pressure of 137/81 mm Hg over 4 years.
Number of subjects: 950
Study 10386412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (group IP) with two cycles of 3 min aortic cross-clamping and 2 min reperfusion before cardioplegic arrest.
Number of subjects: 40
Study 10386412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (group IP)
Number of subjects: 40
Study 10386412 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 40
Study 8682969 — intervention group
Group type: EXPERIMENTAL
Intervention: 585 nm flashlamp‐pumped pulsed dye laser
Number of subjects: 22
Study 8682969 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated scars)
Number of subjects: 22
Study 2071809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercises (taught and monitored for 6 months)
Number of subjects: 157
Study 2071809 — intervention group
Group type: COMPARATOR
Intervention: Phenylpropanolamine hydrochloride (50 mg a day, increasing to 50 mg twice a day)
Number of subjects: 157
Study 6627169 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminders
Number of subjects: 0
Study 6627169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminders
Number of subjects: 0
Study 6627169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 0
Study 28810464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dieted
Number of subjects: 134
Study 28810464 — intervention group
Group type: COMPARATOR
Intervention: One dieted, the other ate normally
Number of subjects: 134
Study 28810464 — intervention group
Group type: COMPARATOR
Intervention: Both ate normally
Number of subjects: 134
Study 28212476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage island tympanoplasty
Number of subjects: 69
Study 28212476 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia
Number of subjects: 69
Study 26499449 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced protocol for case-finding of atrial fibrillation including pulse palpation, automated atrial fibrillation detection, and handheld single-lead ECG.
Number of subjects: 19200
Study 26499449 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced protocol for case-finding of atrial fibrillation.
Number of subjects: 19200
Study 26499449 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 19200
Study 23576128 — intervention group
Group type: COMPARATOR
Intervention: Salience network activity
Number of subjects: 0
Study 23576128 — intervention group
Group type: COMPARATOR
Intervention: Default mode network recruitment
Number of subjects: 0
Study 23576128 — intervention group
Group type: COMPARATOR
Intervention: Granger causality analysis
Number of subjects: 0
Study 21161222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid plus vasopressin (4 IU bolus and 2.4 IU/h infusion for 5 hours)
Number of subjects: 78
Study 21161222 — intervention group
Group type: COMPARATOR
Intervention: Fluid alone (control group)
Number of subjects: 78
Study 19138400 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Number of subjects: 26
Study 19138400 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 26
Study 18693827 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless devices (PDAs and tablet PCs)
Number of subjects: 79
Study 18693827 — intervention group
Group type: COMPARATOR
Intervention: Paper assessment module
Number of subjects: 79
Study 15923572 — intervention group
Group type: COMPARATOR
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 587
Study 15923572 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide, cisplatin, paclitaxel, and granulocyte colony-stimulating factor (PET)
Number of subjects: 587
Study 12042191 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 248
Study 12042191 — intervention group
Group type: COMPARATOR
Intervention: Divalproex (500-2500 mg/day in divided doses)
Number of subjects: 248
Study 9676304 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Dextran (D)
Number of subjects: 24
Study 9676304 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte solution (VE)
Number of subjects: 24
Study 7786368 — intervention group
Group type: EXPERIMENTAL
Intervention: AOD curriculum participation
Number of subjects: 25
Study 7786368 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 7786368 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum components
Number of subjects: 25
Study 2193836 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet 500 mg orally twice daily for 7 days
Number of subjects: 41
Study 2193836 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 500 mg orally three times daily for 7 days
Number of subjects: 41
Study 351755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OTB)
Number of subjects: 0
Study 351755 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol (FEN)
Number of subjects: 0
Study 31221489 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief inpatient psychoeducational intervention
Number of subjects: 121
Study 31221489 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 121
Study 28976431 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP score (proportioned spinopelvic state)
Number of subjects: 222
Study 28976431 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately disproportioned spinopelvic state
Number of subjects: 222
Study 28976431 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely disproportioned spinopelvic state
Number of subjects: 222
Study 28976431 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP score
Number of subjects: 222
Study 25789444 — intervention group
Group type: EXPERIMENTAL
Intervention: Water only (treatment A)
Number of subjects: 34
Study 25789444 — intervention group
Group type: EXPERIMENTAL
Intervention: Water + cola (treatment B)
Number of subjects: 34
Study 25789444 — intervention group
Group type: EXPERIMENTAL
Intervention: Water + diet cola (treatment C)
Number of subjects: 34
Study 25789444 — intervention group
Group type: EXPERIMENTAL
Intervention: Water + cola + diet cola + orange juice (treatment D)
Number of subjects: 34
Study 23766337 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration (HDF)
Number of subjects: 0